Robert Hennessey has completed a nine-year term as chairman of Genome Therapeutics of Waltham, Mass. He will continue as a member of the board and Steven Rauscher, presently president and CEO, will become chairman. Hennessey retired as an employee of the company in April.
Glen Sato, senior vice president, chief financial officer, and general counsel for Exelixis of South San Francisco, is leaving the company to return to Protein Design Labs, where he will become CFO, effective in June.
Matthew Mackowski of Telegraph Hill Partners, a San Francisco-based private equity investment firm, has joined Ambion’s board of directors. Mackowski is also on the board of directors of Genomic Solutions, a subsidiary of Harvard Bioscience.
Michael Deines is the new vice president of marketing at Dharmacon. Deines will lead marketing efforts of the Lafayette, Colo., company’s RNA products, including its short interfering RNA (siRNA). Deines comes to Dharmacon from Sigma-Aldrich, where he was vice president of sales and manager of molecular biology marketing in the biotechnology division. Before joining Sigma-Aldrich, Deines worked in a variety of sales positions at Amersham Bioscience.
Zahed Subhan has been appointed CEO of Copenhagen-based Nuevolution. Subhan joins the drug discovery company from Locus Pharmaceuticals, where was vice president of business development. He previously worked at Sanofi Synthelabo, Glaxo Wellcome, Dupont Merck Pharmaceuticals and GeminiGenomics.